Psoriasis
📧 Sign up to get email alerts when something new happens for Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Tilrdakizumab Almirall
A clinical trial evaluating tilrdakizumab for psoriasis is currently active but not recruiting at University Hospital Schleswig-Holstein.
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: Hemoperfusion With Efferon CT for the Treatment of Patients With Severe Psoriasis [NA]
Clinical trial evaluating hemoperfusion with Efferon CT for severe psoriasis has completed.
-
EMA approval · 2025-11-21EMA Authorised: Usgena (ustekinumab) — Stada Arzneimittel AG
The European Medicines Agency authorised Usgena, a ustekinumab product from STADA, for treatment of Crohn's disease, psoriasis, psoriatic ar…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis [Phase 4]
A Phase 4 multicenter randomized double-blind trial evaluated whether adding methotrexate improves and maintains response to anti-TNF therap…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis [Phase 2]
A Phase 2 trial evaluating SAR441566 in adults with plaque psoriasis has completed and results have been posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-11-10EMA Authorised: Flixabi (infliximab) — Samsung Bioepis NL B.V.
The EMA authorised Flixabi, a biosimilar of infliximab, for several inflammatory diseases. The indications include rheumatoid arthritis, pso…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
A clinical trial is evaluating an educational tool to help melanoma patients with pre-existing autoimmune diseases who are candidates for im…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Risankizumab Long-term Remission Study [Phase 4]
Update on the Phase 4 Risankizumab long-term remission study shows the trial is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: High Dose Risankizumab for Psoriasis [Phase 2]
A Phase 2 trial evaluating high-dose risankizumab for psoriasis has completed, with results posted on 2025-10-24.
-
EMA approval · 2025-10-22EMA Authorised: Amsparity (adalimumab) — Pfizer Europe MA EEIG
EMA authorised Amsparity (adalimumab) from Pfizer Europe MA EEIG. The biosimilar is approved for multiple autoimmune indications including r…
-
EMA approval · 2025-10-21EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Idacio, a biosimilar of adalimumab, for multiple inflammatory diseases, produced by Fresenius Kabi Deutschland GmbH. The indi…
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis [Phase 3]
Long-term Phase 3 trial assessing the safety and efficacy of Deucravacitinib for psoriasis; the study is currently active but not recruiting…
-
EMA approval · 2025-10-08EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Humira (adalimumab) by AbbVie Deutschland GmbH & Co. KG for multiple indications including ankylosing spondylitis, juveni…
-
CLINICAL_TRIALS trial_result · 2025-10-06Clinical Trial Update: Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases [NA]
Clinical trial update on a high-touch, low-cost approach to improving mental health outcomes in patients with psoriatic diseases; the study …
-
FDA approval · 2025-10-03FDA Approved: CALCIPOTRIENE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for Calcipotriene from Prasco Laboratories, indicating an addition or modification to the drug's exi…
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis [Phase 1, Phase 2]
Proof-of-concept Phase 1/2 study of AX-158 in patients with mild to moderate plaque psoriasis has completed.
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study [Phase 4]
Phase 4 MEMPSOLAR trial evaluating residual disease memory in psoriasis skin during EnstiLAR therapy and narrow-band UVB treatment; the stud…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Safety and Efficacy of RAP-103 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects [Phase 2]
A Phase 2 clinical trial update describes safety and efficacy goals for RAP-103 in adults with moderate-to-severe psoriasis; the study is no…
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis [Phase 1]
Phase 1 trial evaluating safety, tolerability, and clinical response of SAR441566 versus placebo in mild to moderate psoriasis. The study st…
-
CLINICAL_TRIALS trial_result · 2025-09-24Clinical Trial Update: Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis
A clinical trial update on the efficacy of tildrakizumab for difficult-to-treat areas of psoriasis (palmar, genital, scalp, plantar, and nai…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis
Phase 4 multicenter, open-label trial evaluating the efficacy and safety of apremilast in moderate-to-severe psoriasis. Sponsored by Daewoon…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction [NA]
A clinical trial is evaluating a novel skin barrier product against petrolatum for skin barrier dysfunction and is currently recruiting at M…
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®) [Phase 1]
A Phase 1 drug-drug interaction study assessed how HS-10374 interacts with Yasmin (drospirenone/ethinyl estradiol) in participants with psor…
-
CLINICAL_TRIALS trial_result · 2025-09-17Clinical Trial Update: Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
A completed clinical trial in Taiwan evaluated changes in psoriasis disease state after subcutaneous risankizumab in adults. The study was s…
-
FDA approval · 2025-09-16FDA Approved: FLUOCINOLONE ACETONIDE OIL — Supplemental Application (RISING PHARMA HOLDINGS, INC.)
FDA approved a supplemental application to add Fluocinolone Acetonide Oil as an approved topical formulation of fluocinolone acetonide by Ri…